Related by context. All words. (Click for frequent words.) 69 folate analogue metabolic 67 ® C1 esterase 66 liposomal formulation 65 Kahalalide F 65 glycoprotein GP IIb IIIa 64 HCV RNA polymerase 64 novel histone deacetylase 64 generation purine nucleoside 64 SGLT 64 BLyS specific 64 dasatinib Sprycel 63 mTOR kinase 63 targeted tyrosine kinase 63 statin HMG CoA reductase 63 HQK 63 PRT# 63 polymerase inhibitor 62 Kinase Inhibitor 62 JAK#/JAK# 62 GW# [003] 62 investigational HCV polymerase 62 small molecule tyrosine 62 SGLT 2 62 gemcitabine cisplatin 62 IAP inhibitor 61 Degarelix 61 histamine dihydrochloride 61 receptor tyrosine kinase inhibitor 61 Liposomal 61 Hsp# Inhibitor 61 cytidine nucleoside analog 61 volociximab 61 urocortin 2 61 Polymerase Inhibitor 61 potent suppressor 61 Bosutinib 61 Maribavir 61 BrachySil TM 61 targeted antifolate 61 dasatinib Sprycel ® 61 BIM #A# 61 orally dosed 61 HGS# 60 FVIIa 60 epothilones 60 cortisol synthesis 60 estramustine 60 potent topoisomerase II 60 pegfilgrastim 60 Monoclonal antibody 60 PDE4 inhibitor 60 CCR5 antagonist 60 Bruton tyrosine kinase 60 Aflibercept 60 trabectedin 60 Aurora Kinase 60 Angiotensin converting enzyme ACE 60 Bruton tyrosine kinase Btk 60 TRO# 60 PSMA ADC 60 antimitotic 60 oral picoplatin 60 vinorelbine tartrate 60 intratumoral injection 60 Beta catenin pathway 60 ChronVac C R 60 phosphatidylserine PS targeting 60 Pertuzumab 60 Bendamustine 60 isoform selective 60 intranasal formulation 60 Investigational Oral 60 MAGE A3 ASCI 59 protein tyrosine phosphatase 1B 59 huN# DM1 59 Tarceva TM 59 M1 muscarinic 59 Pharmacokinetics PK 59 novel emulsion formulation 59 tyrosine kinase inhibitor 59 Quinamed 59 accumulate preferentially 59 vascular disrupting agent 59 Cloretazine ® 59 Forodesine 59 Pemetrexed 59 CG# [003] 59 selective estrogen receptor modulator 59 Copegus ribavirin 59 multi kinase inhibitor 59 mediated inhibition 59 vinca alkaloid 59 rALLy clinical trial 59 histone deacetylase HDAC inhibitor 59 pertuzumab 59 bortezomib Velcade 59 Factor VIIa 59 PEGylated interferon 59 Tyrosine Kinase Inhibitor 59 PI3K inhibitor 59 nucleotide analog 59 Temsirolimus 59 YONDELIS 59 chimeric monoclonal antibody 59 AEG# 59 mitogen activated ERK kinase 59 dipeptidyl peptidase IV 59 cMet 59 multikinase inhibitor 59 Gleevec resistant 59 Kinoid 59 Plicera 59 Omacetaxine 59 LB# [003] 59 CCR5 inhibitor 59 Telatinib 59 corticosteroid dexamethasone 59 pan HDAC inhibitor 59 beta 1a 59 5 Fluorouracil 59 TLK# 59 systemic RNAi therapeutic 59 CELLECTRA ® 59 samalizumab 58 5 HT2A serotonin 58 targeted radiotherapeutic 58 HuCAL antibodies 58 oral renin inhibitor 58 non nucleoside HCV 58 Archexin 58 mTOR inhibitor 58 Gefitinib 58 preclinical efficacy 58 subcutaneously administered 58 Erlotinib 58 Irinotecan 58 Panzem R NCD 58 EGFR receptor 58 Spiegelmer ® 58 reversible inhibitor 58 liposomal doxorubicin 58 triciribine phosphate monohydrate 58 antibody MAb 58 5 fluorouracil leucovorin 58 #I TM# 58 adalimumab Humira 58 PEGPH# 58 Peginterferon 58 humanised monoclonal antibody 58 Sorafenib Nexavar 58 mda 7 58 Prodarsan R 58 Soliris eculizumab 58 paclitaxel Taxol 58 Iluvien TM 58 oral proteasome inhibitor 58 decitabine 58 HSP# inhibitor 58 fosbretabulin 58 Interferon alfa 58 humanized monoclonal 58 ALN HTT 58 Enkephalin 58 Angiotensin Converting Enzyme 58 cathepsin K inhibitor 58 Akt activation 58 aurora kinase inhibitor 58 HuMax 58 renin inhibitor 58 Reverset 58 Neuvenge 58 GRNVAC1 58 poly ADP ribose polymerase 58 mineralocorticoid receptor 58 antiapoptotic 58 Ad5FGF 4 58 recombinant biopharmaceutical 58 lenalidomide Revlimid R 58 Noxafil 58 Initiates Clinical 58 DNA intercalator 58 DepoVax 58 selective antagonist 58 Bellicum 58 ospemifene 58 RhuDex ® 58 selectively inhibited 58 Phase #b/#a trial 58 HuLuc# 58 cilengitide 58 null responder 58 omacetaxine mepesuccinate 58 complete cytogenetic response 58 Glufosfamide 58 PI3K/mTOR 58 PRX# 58 Sipuleucel T 58 prostanoid 58 ENMD # 57 EGFR TKI 57 anti tumor necrosis 57 ANAVEX #-# [001] 57 CD8 + cytotoxic 57 Amrubicin 57 PEG IFN 57 oral Azacitidine 57 ISF# 57 Janus Kinase 57 Anavex #-# 57 relapsed MM 57 PF # [002] 57 pain palliation 57 PegIFN 57 epoetin alpha 57 Interferon beta 57 subcutaneous immunoglobulin 57 potently inhibit 57 successfully commercialize Iluvien 57 stated Michelle Berrey 57 administered subcutaneously 57 ribavirin RBV 57 Janus kinase 57 TOCOSOL 57 MGd 57 Mipomersen 57 imatinib Gleevec ® 57 Dacogen decitabine 57 refractory ovarian cancer 57 KRN# 57 E1 INT TM 57 rxRNA 57 sorafenib Nexavar 57 antiangiogenic agent 57 Spiegelmer 57 immune modulating 57 IRX 2 57 PRLX # 57 selectively binds 57 paclitaxel poliglumex 57 Trofex 57 TLR9 agonist 57 cetuximab Erbitux R 57 personalized dendritic 57 systemic RNAi 57 topically administered 57 intranasal delivery 57 irreversible inhibitor 57 nucleotide reverse transcriptase 57 Alfacell proprietary ribonuclease 57 DXL# 57 metastatic malignant 57 Files IND 57 Aztreonam 57 Annamycin 57 ixabepilone 57 highly selective endothelin 57 virus AAV 57 Anticalin R 57 DP b# 57 GHRH 57 Cumulase 57 multiple myeloma MM 57 gastrointestinal stromal tumors GIST 57 Vascular Disrupting Agent 57 Capesaris 57 non nucleoside 57 Vilazodone 57 acetylcholinesterase AChE 57 BCG refractory 57 binds selectively 57 ispinesib administered 57 mertansine 57 Qutenza TM 57 Btk inhibitor 57 inhibit oxidative stress 57 HDAC Inhibitor 57 KSP inhibitor 57 CIMZIA TM 57 PROCHYMAL 57 Cloretazine 57 Micromet BiTE 57 NeoLipid R 57 DNA demethylating agent 57 PHX# 57 Synta Announces 57 CELLECTRA R 57 Talotrexin 57 retaspimycin hydrochloride 57 kinesin spindle protein KSP 57 Poly ICLC 56 BCR ABL inhibitor 56 gefitinib Iressa 56 Ganciclovir 56 selective modulator 56 PORxin TM 56 HCV NS3 protease 56 dihydrofolate reductase 56 Flt3 56 cyclin dependent kinase CDK 56 sodium glucose cotransporter 56 SAR# [004] 56 Yondelis ® 56 histone deacetylase inhibitor 56 Pathway Inhibitor 56 antiproliferative activity 56 cytotoxic T lymphocyte 56 aurora kinase 56 highly selective inhibitor 56 NOD SCID mice 56 Mycophenolate Mofetil 56 NM# [003] 56 Myelodysplastic Syndrome MDS 56 docetaxel Taxotere 56 Indomethacin 56 CRLX# 56 Lenalidomide 56 proteasome inhibitor 56 erlotinib Tarceva ® 56 vascular disrupting agents 56 Triapine 56 Intravitreal 56 Granted Orphan Drug 56 taxane derivative 56 Belerofon 56 methionine aminopeptidase 56 Neoadjuvant 56 histone deacetylase HDAC 56 Allovectin 7 56 riociguat 56 HCV nucleoside 56 potently inhibits 56 selective serotonin 2C receptor 56 oral treprostinil 56 somatostatin analogue 56 Exemestane 56 melphalan prednisone 56 nonnucleoside reverse transcriptase inhibitors 56 Cyclophosphamide 56 Gemzar gemcitabine 56 bevacizumab Avastin ® 56 mRCC 56 selective agonist 56 nucleoside analog 56 OMAPRO 56 inhibit EGFR 56 Melphalan 56 Kamada AAT 56 siRNA therapeutic 56 PSN# [001] 56 Capsulution 56 busulfan 56 Bortezomib 56 vivo validation 56 metastatic colorectal 56 plasmid encoding 56 Phase 2a trial 56 p# biomarker 56 CDK inhibitor 56 CRAC channel 56 tubulin inhibitor 56 Cimzia TM 56 OHR/AVR# 56 Technosphere ® 56 dihydrofolate reductase DHFR 56 ® natalizumab 56 IND submission 56 Proteasome 56 intradermal injections 56 demonstrated antitumor activity 56 SCIg 56 ZACTIMA 56 viral kinetics 56 progressive metastatic prostate 56 cetuximab Erbitux ® 56 APTIVUS 56 Phase IIa Trial 56 PKC# 56 matrix metalloproteases 56 Convivia TM 56 LHRH 56 rhMBL 56 Evamist TM 56 thalidomide Thalomid 56 biologic therapy 56 vidofludimus 56 Evoltra ® 56 HDACi 56 Curaxin 56 DEB# 56 SR# [004] 56 refractory prostate cancer 56 cyclin dependent kinase inhibitor 56 pharmacokinetic PK study 56 ESBA# 56 biliary tract cancer 56 steroid sulfatase 56 NeuVax 56 LHRH receptor positive 56 PrevOnco 56 assessing T DM1 56 topoisomerase II inhibitor 56 BUPHENYL R sodium phenylbutyrate 56 Guanilib 56 rFSH 56 isoenzyme 56 oral talactoferrin 56 VitiGam TM 56 PRO# [003] 56 epigenetic therapies 56 novel anticancer 56 immunomodulatory therapy 56 refractory chronic lymphocytic 56 albumin bound paclitaxel 56 Protein Kinase C 56 #mg/#mg 56 negative allosteric modulator 56 trabedersen 55 HuMax CD4 55 potently inhibited 55 VEGF receptor 55 anti CD3 55 insulin glulisine 55 Darusentan 55 thymidylate synthase TS 55 ChronVac C ® 55 LEUKINE 55 IFN α 55 dose dexamethasone 55 Valtropin 55 therapeutic monoclonal antibody 55 rt PA 55 LymphoStat B TM 55 Zybrestat 55 dexamethasone Decadron 55 Aerosurf 55 Phase Ib clinical 55 mTOR inhibitors 55 OMNARIS HFA 55 humanized monoclonal antibody 55 somatostatin analog 55 Trastuzumab 55 p# inhibitor 55 Orally administered 55 Azacitidine 55 certolizumab 55 hypoxia activated prodrug 55 SERCA2a 55 Pegylated Liposomal Doxorubicin 55 CINQUIL 55 ARRY # 55 intracellular accumulation 55 regorafenib 55 mg kg BID 55 ACC2 55 thymidylate synthase 55 Ixabepilone 55 recombinant FVIII 55 DMAG 55 telomerase activator 55 receptor blocker 55 Potelligent Technology 55 UPLYSO 55 VNP#M 55 Systemic Delivery 55 Anticalin ® 55 obatoclax 55 IIa trial 55 lapatinib Tykerb 55 tipifarnib 55 relapsed ovarian cancer 55 alfa 2a 55 Tumor Necrosis Factor 55 Ceflatonin 55 Gamma secretase 55 prostaglandin synthesis 55 cytostatic 55 HDL Selective Delipidation 55 OncoGel 55 chemokine receptor 55 Pharmacokinetic studies 55 directed radiotherapeutic antibody 55 CXCR4 antagonist 55 MGN# 55 IDO inhibitor 55 NOX E# 55 radiolabelled 55 Enzyme Replacement Therapy 55 gemcitabine carboplatin 55 selective adenosine 55 thrombin receptor 55 ACE angiotensin converting enzyme 55 HCV polymerase 55 antitumor effect 55 LEAPS TM 55 PPARgamma 55 MEK ERK 55 4mg/kg 55 bevacizumab Avastin R 55 calcitonin gene related 55 EndoTAG TM -1 55 SYN# 55 pegylated alpha interferon 55 CRACM 55 Traficet EN 55 ISTODAX 55 inhaled AAT 55 denileukin diftitox 55 MET VEGFR2 55 Cytotoxic 55 ara C 55 Patients Treated With 55 humanized antibody 55 platelet inhibitor 55 EGFR HER 55 Zmax 55 EndoTAG TM 55 Pfizer Selzentry 55 Raf kinase 55 mapatumumab 55 Pegylated Interferon 55 pegylated interferon alpha 55 VMAT2 55 receptor antagonism 55 Inhalation Solution 55 Anthim 55 skeletal sarcomere activators 55 pegylated liposomal doxorubicin 55 TransVax tm 55 BRAF inhibitors 55 glucagon receptor 55 resolvin 55 EDEMA3 55 Fingolimod 55 mesylate 55 ritonavir boosted 55 RhuDex R 55 vivo preclinical 55 Albuferon albinterferon alfa 2b 55 Hematopoietic 55 long acting muscarinic 55 cutaneous T 55 Hsp# inhibitor 55 potent cytotoxic 55 sunitinib malate 55 HuMax TAC 55 Epothilone 55 colon carcinoma 55 gemcitabine Gemzar ® 55 immunotherapeutic vaccine 55 taxane refractory 55 thromboxane A2 55 Gonal f ® 55 dimeglumine 55 Cand5 55 EGFR TKIs 55 Cyclosporin 55 Intravail ® 55 antisense oligonucleotide 55 etoposide 55 Vinorelbine 55 ARC# [001] 55 Initiate Clinical Trial 55 murine monoclonal antibody 55 hypomethylating agent 54 Junovan TM 54 PGL# 54 cyclin dependent kinases 54 Submits IND 54 pentamidine 54 FOLFOX6 54 eribulin mesylate 54 adenoviral vectors 54 Annexin V 54 Histone deacetylase 54 receptor monoclonal antibody 54 Fluconazole 54 IL-#/# 54 glycopeptide 54 lipopeptide 54 receptor modulators 54 MDS AML 54 TNF alpha inhibitor 54 Olaparib 54 acid phosphatase PAP 54 Receptor Agonist 54 bazedoxifene selective estrogen receptor 54 NS4A 54 BHT DNA 54 HER2 overexpression 54 Tacrolimus 54 tumor vascular disrupting 54 Exendin 4 54 Activity Assay 54 anticancer compound 54 AN# novel 54 oxymorphone ER 54 paclitaxel Taxol R 54 heparanase 54 inhibit replication 54 nanomolar range 54 Cyclooxygenase 54 PETNET Solutions 54 Adrenergic 54 Cathepsin S 54 trastuzumab Herceptin 54 sterile lidocaine patch 54 EOquin TM 54 vivo potency 54 ACOMPLIA R 54 IRESSA 54 gemcitabine Gemzar 54 Granulocyte Colony Stimulating Factor 54 intravesical instillation 54 isatoribine 54 Anticancer Compound 54 lenalidomide Revlimid 54 CONBRIZA 54 valopicitabine NM# 54 radiotherapeutic 54 selective inhibitor 54 monoclonal antibody conjugated 54 liposomal amphotericin B 54 midstage clinical 54 JAK2 inhibitor 54 adenosine A2A 54 REMINYL ® 54 Trobalt 54 nucleotide analog polymerase inhibitor 54 BrachySil ™ 54 3 kinase PI3K 54 SIR Spheres 54 ZFP Therapeutics 54 immunosuppressant drug 54 relapsed multiple myeloma 54 MTP inhibitor 54 Recombinant Human 54 selective inhibition 54 AQ4N 54 RH1 54 alemtuzumab Campath 54 alglucosidase alfa 54 miconazole Lauriad R 54 Tyrosine Kinase Inhibitors 54 CDK4 54 interstitial brachytherapy 54 PD LID 54 DCCR 54 Zensana TM 54 verteporfin 54 XL# XL# XL# 54 Ancrod 54 Neulasta ® 54 refractory chronic myeloid 54 beta estradiol 54 AERx iDMS 54 inhibitor RG# 54 gets USFDA nod 54 Vascugel ® 54 GPIIb IIIa 54 Surfaxin LS 54 basiliximab 54 FLT3 54 antiviral potency 54 Dr. Fahar Merchant 54 Immunomodulatory 54 mitotic kinesin 54 S#P# 54 Cinacalcet HCl 54 depsipeptide 54 GeneICE 54 ERK5 54 Chimigen TM 54 protease inhibitor PI 54 HER1 54 IL6 54 adult mesenchymal stem 54 plasmid DNA pDNA 54 RTP #i 54 NOX4 54 imatinib mesylate Gleevec 54 Celator 54 colony stimulating factor 54 incyclinide 54 ARG# 54 astemizole 54 Cetuximab Erbitux 54 NP2 Enkephalin 54 biased ligand 54 phosphoinositide 54 EGFR mutation positive 54 Neupogen ® 54 tiuxetan 54 Phase III ADT 54 NAVISTAR R 54 PRIALT 54 MyVax ® 54 c MYC 54 PDE# inhibitors 54 mutated KRAS 54 Multiple Myeloma MM 54 NF κB pathway 54 ATD Gel 54 alefacept 54 cationic lipid 54 Enzastaurin 54 Bioral Amphotericin B 54 sunitinib Sutent 54 cholesteryl ester transfer 54 leukotriene receptor antagonist 54 Amigal 54 sodium thiosulfate STS 54 demethylating agent 54 AFFITOME R 54 Cutaneous T 54 Tß4 54 liposome formulation 54 IMP# 54 ALN VSP Phase 54 Prodrug 54 imatinib therapy 54 insulin aspart 54 P2Y 54 PN# [001] 54 pancreatic alpha 54 PARP inhibitor 54 rhITF 54 Anti angiogenic 54 MVA BN 54 potent antiproliferative 54 Decitabine 54 CCR1 54 Fenretinide 54 TIMP 1 53 small molecule activators 53 prucalopride 53 humanised antibody 53 novel orally bioavailable 53 Ontak 53 Fludarabine 53 uricase 53 mCRPC 53 AdhTAP 53 muscarinic 53 cisplatin chemotherapy 53 Gemcitabine 53 VEGF inhibitor 53 2 inhibitor CYT# 53 Antiangiogenic 53 hMG 53 XTEN 53 Secretase 53 IMC #B 53 prokinetic 53 farletuzumab 53 FIRMAGON R 53 Cytochrome P# 53 etanercept Enbrel 53 effector function 53 Teysuno 53 REVIVE Diabetes 53 investigational immunotherapy 53 rhIL 7 53 bendamustine 53 tumorigenicity 53 Preclinical studies indicate 53 SCIB1 53 IGF1R 53 DGAT 53 Phase Ib study 53 pharmacodynamic PD 53 Nanobody R 53 antitumor effects 53 kinesin spindle protein 53 Alvesco R 53 predictive toxicology 53 MAb 53 orally inhaled 53 HERCEPTIN 53 relapsing multiple sclerosis 53 Bavarian Nordic patented 53 Immunotherapeutic 53 peptide conjugated 53 essential thrombocythemia ET 53 refractory colorectal cancer 53 NK1R 53 Her2 positive 53 synthetic siRNA 53 fulvestrant 53 eligen 53 Phase Ib Clinical Trial 53 Tie2 53 Ruconest 53 antiangiogenic therapy 53 Oasmia 53 erlotinib Tarceva 53 intradermal injection 53 personalized cellular immunotherapy 53 CytoFabTM 53 Nanobody ® 53 transarterial 53 Torisel 53 ClearPath HDR 53 acyclovir Lauriad ® 53 Resten MP 53 epirubicin cyclophosphamide 53 dexpramipexole 53 antisense inhibitors 53 galiximab 53 Sorafenib 53 Vidaza azacitidine 53 BLP# Liposome Vaccine 53 torsemide ER 53 anti CD3 antibody 53 GSK '# 53 ARIKACE ™ 53 Phase IIb clinical trials 53 opioid naïve 53 recurrent NSCLC 53 vismodegib 53 Aromatase 53 tinzaparin 53 LCP AtorFen 53 QVAR 53 lymphoid malignancies 53 adriamycin 53 intracellular uptake 53 PTK# 53 CINTREDEKIN BESUDOTOX 53 pharmacological chaperone 53 Occlusin TM 53 FBPase 53 pharmacokinetic interactions 53 afamelanotide 53 TBC M4 53 peginterferon alpha 2a 53 GGTase 53 temozolomide Temodar 53 anagrelide 53 molecular chaperone regulation 53 oral ridaforolimus 53 Intravesical 53 CHOP chemotherapy 53 Adult Stem Cell Therapy 53 polycythemia vera essential thrombocythemia 53 M Vax 53 ASSERT trial 53 deacetylase 53 benzimidazole 53 prostate cancer HRPC 53 Phase IIb trials 53 Velcade bortezomib 53 bronchodilatory 53 potent inducer 53 NPC 1C 53 anti TNF alpha 53 bile acid sequestrant 53 Gliadel Wafer 53 Apo AIMilano 53 axitinib 53 BEZ# 53 p# MAP kinase inhibitor 53 pegylated interferon alfa 53 Topoisomerase II 53 5alpha reductase 53 selective progesterone receptor 53 phase IIa clinical 53 downregulates 53 cyclooxygenase COX 53 AMPK activators 53 BCR ABL inhibitors 53 Anticalins R 53 GORE TAG Device 53 dose melphalan 53 EndoTAGTM 1 53 hA# 53 interferon beta therapy 53 EGFR HER2 53 muscarinic antagonist 53 PI3 kinase inhibitors 53 nucleoside polymerase inhibitor 53 rFIXFc 53 JAK1 53 NQO1 53 microtubule inhibitor 53 histone acetyltransferase 53 Thrombin 53 Imatinib 53 tipranavir r 53 paclitaxel carboplatin 53 peptidomimetic 53 CGEN # 53 siRNA therapeutics 53 Erbitux cetuximab 53 GSK# [001] 53 OLpur TM H2H 53 MorphoSys proprietary 53 Fc fusion protein 53 fistulizing Crohn disease 53 HBV vaccine 53 Aggrastat ® tirofiban hydrochloride 53 CorVue ™ 53 HIF PHI 53 tumor regressions 53 sipuleucel T 53 mediated phosphorylation 52 olaparib 52 Phase IIa trials 52 pegylated recombinant 52 Rituxan rituximab 52 Phase Ib II 52 LCP Tacro 52 metastatic neuroendocrine tumors 52 gamma secretase inhibitor 52 sustained virological response 52 fluoropyrimidine 52 Oxaliplatin 52 relapsed refractory 52 TNF α 52 adenoviral 52 Fibroblast Growth Factor Receptor 52 chemotherapeutic regimen 52 Metastatic Melanoma 52 VitiGam 52 antitumoral 52 metastatic renal cell carcinoma 52 histone deacetylase 52 somatostatin receptor 52 oblimersen 52 Daniel Junius 52 colorectal cancer liver metastases 52 antiproliferative effects 52 cMET inhibitor 52 Derived Factor 52 alpha 2a 52 ALK inhibitors 52 Vernakalant 52 resminostat 52 mitomycin 52 subcutaneous SC 52 PPAR peroxisome proliferator activated 52 bFGF 52 VAPRISOL 52 eluting stent 52 TPV r 52 oral taxane 52 delta isoform 52 SGLT2 inhibitors 52 NM# [001] 52 INTERCEPT red 52 VITAL Trial 52 hypereosinophilic syndrome 52 ErbB2 positive 52 BN# [004] 52 StemEx R 52 pentostatin 52 StemEx 52 PLA2 52 Cx# [002] 52 CINtec R 52 miglustat 52 Temozolomide 52 NK1 52 inverse agonist 52 Cyclosert 52 RNA antagonists 52 KuDOS 52 Announces Poster Presentations 52 cediranib 52 MAXY VII 52 peginterferon alpha 52 Glybera R 52 Tumor necrosis factor 52 Flu Cy 52 2DG 52 5 HT2C receptor 52 anticancer activity 52 CYP#A# enzyme 52 aspartyl 52 fluvastatin 52 cardiotoxic 52 Hedgehog antagonist 52 Kinase Inhibitors 52 Thorough QT 52 Angiogenic 52 Topoisomerase 52 micafungin 52 quinolone 52 proteasome inhibitor bortezomib 52 cyclophosphamide methotrexate 52 AERx R 52 Hsp 52 P#Y# [002] 52 oncolytic vaccine 52 autologous SCT 52 HIV reverse transcriptase 52 INGN 52 M2 subunit 52 Naive Patients 52 statistically significant efficacy